FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126137022> ?p ?o ?g. }

• W2126137022 endingPage "548" @default.
• W2126137022 startingPage "548" @default.
• W2126137022 abstract "Back to table of contents Previous article Next article Letter to the EditorFull AccessTrimipramine for Refractory Panic AttacksDOMINGO CERRA, M.D., DOMINGO CERRASearch for more papers by this author, M.D., Ocala, Fla.Published Online:1 Mar 2006https://doi.org/10.1176/appi.ajp.163.3.548AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor:Trimipramine, a tricyclic tertiary amine pharmacologically related to imipramine, which was the first pharmacological agent noted to treat panic disorders (1), provides significant rapid antipanic effects with minimal side effects at a low dose. Tricyclic drugs are less widely used than selective serotonin reuptake inhibitors (SSRIs) because tricyclic drugs generally have more severe adverse effects at the higher doses required for effective treatment of panic disorders (2). This is a case report about a man with a 20-year history of panic disorders who was unresponsive to all agents tried, with the exception of imipramine, which was discontinued because of side effects. Tripramine at 50 mg/day induced remission of the panic attacks without adverse effects.Mr. A, a 41-year-old white man, had suffered from panic attacks since age 21. According to Mr. A, the medications tried to no avail (either were ineffective or were discontinued because of side effects) included amitriptyline, bupropion, amoxapine, fluoxetine, sertraline, citalopram, paroxetine, fluvoxamine, duloxetine, escitalopram, carbamazepine, valproic acid, lithium, olanzapine, aripiprazole, olanzapine plus fluoxetine, aripiprazole plus fluoxetine, clonazepam, lorazepam, alprazolam, and combinations of alprazolam with multiple SSRIs, atypical neuroleptics, tricyclics, tetracyclics, and anticonvulsants.Mr. A was initially seen while taking fluoxetine, 20 mg/day, in addition to 8 mg/day of alprazolam with olanzapine, 10 mg/day, and he continued to experience 1–2 panic attacks every 10 days. He had been taking alprazolam for 14 years. Fluoxetine and olanzapine were discontinued, and mirtazapine, 15 mg at night, was begun with the longstanding alprazolam, 2 mg/day. Mirtazapine caused stimulation and was discontinued. Quetiapine, 25 mg/day, was tried in conjunction with 2 mg/day of alprazolam. Quetiapine had to be discontinued because of gastrointestinal side effects. Desipramine was started at 10 mg at bedtime. The dose was increased to 20 mg at bedtime within a 2-week span, but it had to be discontinued because of overstimulation and worsening of the panic attacks. Trimipramine was begun at 25 mg/day, together with alprazolam, 2 mg/day. In view of no side effects, the dose of trimipramine was increased to 50 mg in the morning together with 2 mg/day of alprazolam. Within 5 weeks, Mr. A indicated he was “much calmer” and had not experienced any panic attacks. He remained free of panic attacks for 6 months. Ongoing tapering of alprazolam was being pursued.On the basis of this case report, further use of trimipramine may be warranted in the treatment of panic disorders unresponsive to the more commonly used treatment modalities.References1. Rosenbaum JF, Pollack MH: Panic Disorder and Its Treatment. New York, Marcel Dekker, 1998, pp 160-161Google Scholar2. Sadock BJ, Sadock VA: Panic disorder and agoraphobia, in Kaplan and Sadock’s Concise Textbook of Clinical Psychiatry, 2nd ed. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 606-607Google Scholar FiguresReferencesCited byDetailsCited byTerms and conditions apply: the effect of probation length and obligation disclosure on true and false guilty pleas26 November 2022 | Journal of Experimental Criminology, Vol. 8The Justice Gap and the Promise of Criminological Research. Russian Journal of Economics and Law10 September 2022 | Russian Journal of Economics and Law, Vol. 16, No. 3Diminished culpability in fetal alcohol spectrum disorders (FASD)8 October 2021 | Behavioral Sciences & the Law, Vol. 40, No. 1Neuroimaging Evidence in US CourtsThe criminal costs of wrongful convictions2 September 2019 | Criminology & Public Policy, Vol. 19, No. 2Firmament or Folly? Protecting the Innocent, Promoting Capital Punishment, and the Paradoxes of Reconciliation3 May 2011 | Justice Quarterly, Vol. 29, No. 2Neuroimaging, Diminished Capacity and Mitigation16 March 2012Law and Human Behavior, Vol. 35, No. 5Revista Brasileira de Psiquiatria, Vol. 29, No. suppl 2 Volume 163Issue 3 March 2006Pages 548-548 Metrics PDF download History Published online 1 March 2006 Published in print 1 March 2006" @default.
• W2126137022 created "2016-06-24" @default.
• W2126137022 creator A5087771019 @default.
• W2126137022 date "2006-03-01" @default.
• W2126137022 modified "2023-09-29" @default.
• W2126137022 title "Trimipramine for Refractory Panic Attacks" @default.
• W2126137022 cites W615796854 @default.
• W2126137022 doi "https://doi.org/10.1176/appi.ajp.163.3.548" @default.
• W2126137022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16513887" @default.
• W2126137022 hasPublicationYear "2006" @default.
• W2126137022 type Work @default.
• W2126137022 sameAs 2126137022 @default.
• W2126137022 citedByCount "10" @default.
• W2126137022 countsByYear W21261370222012 @default.
• W2126137022 countsByYear W21261370222019 @default.
• W2126137022 countsByYear W21261370222021 @default.
• W2126137022 countsByYear W21261370222022 @default.
• W2126137022 crossrefType "journal-article" @default.
• W2126137022 hasAuthorship W2126137022A5087771019 @default.
• W2126137022 hasConcept C118552586 @default.
• W2126137022 hasConcept C126322002 @default.
• W2126137022 hasConcept C142724271 @default.
• W2126137022 hasConcept C15744967 @default.
• W2126137022 hasConcept C170493617 @default.
• W2126137022 hasConcept C204787440 @default.
• W2126137022 hasConcept C2775864247 @default.
• W2126137022 hasConcept C2776134451 @default.
• W2126137022 hasConcept C2776412080 @default.
• W2126137022 hasConcept C2776619155 @default.
• W2126137022 hasConcept C2777196872 @default.
• W2126137022 hasConcept C2777529043 @default.
• W2126137022 hasConcept C2777669559 @default.
• W2126137022 hasConcept C2777828372 @default.
• W2126137022 hasConcept C2777843972 @default.
• W2126137022 hasConcept C2778186239 @default.
• W2126137022 hasConcept C2779145073 @default.
• W2126137022 hasConcept C2779177272 @default.
• W2126137022 hasConcept C2779253243 @default.
• W2126137022 hasConcept C2779426884 @default.
• W2126137022 hasConcept C2779583969 @default.
• W2126137022 hasConcept C2779706987 @default.
• W2126137022 hasConcept C2779908668 @default.
• W2126137022 hasConcept C2779910183 @default.
• W2126137022 hasConcept C2780211496 @default.
• W2126137022 hasConcept C2780712732 @default.
• W2126137022 hasConcept C2781081902 @default.
• W2126137022 hasConcept C558461103 @default.
• W2126137022 hasConcept C71924100 @default.
• W2126137022 hasConcept C98274493 @default.
• W2126137022 hasConceptScore W2126137022C118552586 @default.
• W2126137022 hasConceptScore W2126137022C126322002 @default.
• W2126137022 hasConceptScore W2126137022C142724271 @default.
• W2126137022 hasConceptScore W2126137022C15744967 @default.
• W2126137022 hasConceptScore W2126137022C170493617 @default.
• W2126137022 hasConceptScore W2126137022C204787440 @default.
• W2126137022 hasConceptScore W2126137022C2775864247 @default.
• W2126137022 hasConceptScore W2126137022C2776134451 @default.
• W2126137022 hasConceptScore W2126137022C2776412080 @default.
• W2126137022 hasConceptScore W2126137022C2776619155 @default.
• W2126137022 hasConceptScore W2126137022C2777196872 @default.
• W2126137022 hasConceptScore W2126137022C2777529043 @default.
• W2126137022 hasConceptScore W2126137022C2777669559 @default.
• W2126137022 hasConceptScore W2126137022C2777828372 @default.
• W2126137022 hasConceptScore W2126137022C2777843972 @default.
• W2126137022 hasConceptScore W2126137022C2778186239 @default.
• W2126137022 hasConceptScore W2126137022C2779145073 @default.
• W2126137022 hasConceptScore W2126137022C2779177272 @default.
• W2126137022 hasConceptScore W2126137022C2779253243 @default.
• W2126137022 hasConceptScore W2126137022C2779426884 @default.
• W2126137022 hasConceptScore W2126137022C2779583969 @default.
• W2126137022 hasConceptScore W2126137022C2779706987 @default.
• W2126137022 hasConceptScore W2126137022C2779908668 @default.
• W2126137022 hasConceptScore W2126137022C2779910183 @default.
• W2126137022 hasConceptScore W2126137022C2780211496 @default.
• W2126137022 hasConceptScore W2126137022C2780712732 @default.
• W2126137022 hasConceptScore W2126137022C2781081902 @default.
• W2126137022 hasConceptScore W2126137022C558461103 @default.
• W2126137022 hasConceptScore W2126137022C71924100 @default.
• W2126137022 hasConceptScore W2126137022C98274493 @default.
• W2126137022 hasIssue "3" @default.
• W2126137022 hasLocation W21261370221 @default.
• W2126137022 hasLocation W21261370222 @default.
• W2126137022 hasOpenAccess W2126137022 @default.
• W2126137022 hasPrimaryLocation W21261370221 @default.
• W2126137022 hasRelatedWork W1487994801 @default.
• W2126137022 hasRelatedWork W1560455169 @default.
• W2126137022 hasRelatedWork W1996759069 @default.
• W2126137022 hasRelatedWork W2031669980 @default.
• W2126137022 hasRelatedWork W2126137022 @default.
• W2126137022 hasRelatedWork W2319347338 @default.
• W2126137022 hasRelatedWork W2409533190 @default.
• W2126137022 hasRelatedWork W2762695508 @default.
• W2126137022 hasRelatedWork W3092926370 @default.
• W2126137022 hasRelatedWork W4312691400 @default.
• W2126137022 hasVolume "163" @default.
• W2126137022 isParatext "false" @default.
• W2126137022 isRetracted "false" @default.
• W2126137022 magId "2126137022" @default.

• next